Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Biotechnology Annual Review

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1387-2656(02)08007-9PMID 12436918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tek/Tie2 Signaling: New and Old Partners

  2004cited by this paper
• Tie receptors: new modulators of angiogenic and lymphangiogenic responses

  2001cited by this paper
• Angiogenesis: the role of the microenvironment in flipping the switch.

  2001cited by this paper
• Pharmacokinetic/pharmacodynamic modeling in drug targeting

  2001cited by this paper
• Activation of NF-κB via the IκB Kinase Complex Is Both Essential and Sufficient for Proinflammatory Gene Expression in Primary Endothelial Cells*

  2001cited by this paper
• Pharmacological aspects of targeting cancer gene therapy to endothelial cells.

  2001cited by this paper
• Phage Display Technology for Target Discovery in Drug Delivery Research

  2001cited by this paper
• Use of serial analysis of gene expression (SAGE) technology.

  2001cited by this paper
• Pattern of Cytokine and Adhesion Molecule mRNA in Hapten-Induced Relapsing Colon Inflammation in the Rat

  2001cited by this paper
• Development of Proteinaceous Drug Targeting Constructs Using Chemical and Recombinant DNA Approaches

  2001cited by this paper
• Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.

  2001cited by this paper
• Targeting of superoxide dismutase and catalase to vascular endothelium.

  2001cited by this paper
• Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells.

  2001cited by this paper
• Angiogenesis and prostate cancer: identification of a molecular progression switch.

  2001cited by this paper
• Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice.

  2001cited by this paper
• Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105).

  2001cited by this paper
• Cellular distribution and handling of liver-targeting preparations in human livers studied by a liver lobe perfusion.

  2001cited by this paper
• Heterogeneity of the signal transduction pathways for VEGF‐induced MAPKs activation in human vascular endothelial cells

  2001cited by this paper
• A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.

  2001cited by this paper
• Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin

  2001cited by this paper
• Drug Targeting: Basic Concepts and Novel Advances

  2001cited by this paper
• Drug Targeting: Organ-Specific Strategies

  2001cited by this paper
• An SV40 large T-antigen immortalized human umbilical vein endothelial cell line for anti-endothelial cell antibody detection.

  2001cited by this paper
• Bi-specific antibody therapy for the treatment of cancer.

  2001cited by this paper
• Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography.

  2001cited by this paper
• Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography

  2001cited by this paper
• FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition.

  2001cited by this paper
• Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.

  2001cited by this paper
• HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression

  2001cited by this paper
• Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells.

  2001cited by this paper
• Interleukin-1beta in antigen-induced arthritis of the rabbit temporomandibular joint.

  2001cited by this paper
• Integrin activation controls metastasis in human breast cancer.

  2001cited by this paper
• Signaling angiogenesis via p42/p44 MAP kinase and hypoxia.

  2000cited by this paper
• Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)

  2000cited by this paper
• Antibody humanization: a case of the 'Emperor's new clothes'?

  2000cited by this paper
• Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries.

  2000cited by this paper
• Genomics, gene expression and DNA arrays

  2000cited by this paper
• Isolation of endothelial cells from murine tissue.

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Vascular-specific growth factors and blood vessel formation

  2000cited by this paper
• Synthetic DNA delivery systems

  2000cited by this paper
• Recent advances in cellular, sub-cellular and molecular targeting.

  2000cited by this paper
• Evaluation of a radiolabelled cyclic DTPA‐RGD analogue for tumour imaging and radionuclide therapy

  2000cited by this paper
• Genes expressed in human tumor endothelium.

  2000cited by this paper
• Phosphatidylinositol 3-Kinase Signaling Controls Levels of Hypoxia-inducible Factor 11

  2000cited by this paper
• Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

  2000cited by this paper
• Inhibition of angiogenesis and tumour growth by VEGF121–toxin conjugate: differential effect on proliferating endothelial cells

  2000cited by this paper
• A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells.

  2000cited by this paper
• VEGF receptor signaling in tumor angiogenesis.

  2000cited by this paper
• Carbon Monoxide Generated by Heme Oxygenase 1 Suppresses Endothelial Cell Apoptosis

  2000cited by this paper
• Regulation of angiogenesis via vascular endothelial growth factor receptors.

  2000cited by this paper
• Chemokine receptors and their role in inflammation and infectious diseases.

  2000cited by this paper
• Immortalisation of human bone marrow endothelial cells: characterisation of new cell lines

  2000cited by this paper
• Lysosome membrane permeability: implications for drug delivery.

  2000cited by this paper
• Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

  2000cited by this paper
• Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin.

  2000cited by this paper
• An address system in the vasculature of normal tissues and tumors.

  2000cited by this paper
• Critical Evaluation of ECV304 as a Human Endothelial Cell Model Defined by Genetic Analysis and Functional Responses: A Comparison with the Human Bladder Cancer Derived Epithelial Cell Line T24/83

  2000cited by this paper
• Target molecules for anti-angiogenic therapy: from basic research to clinical trials.

  2000cited by this paper
• Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis.

  2000cited by this paper
• VCAM-1, but Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice

  2000cited by this paper
• Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin

  1999cited by this paper
• Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist.

  1999cited by this paper
• IL-4 selectively inhibits IL-2-triggered Stat5 activation, but not proliferation, in human T cells.

  1999cited by this paper
• Immunohistochemical expression of vascular endothelial growth factor/vascular permeability factor in atherosclerotic intimas of human coronary arteries.

  1999cited by this paper
• Elevated Serum Vascular Endothelial Growth Factor in Children and Young Adults with Crohn's Disease

  1999cited by this paper
• Tumor targeting with a selective gelatinase inhibitor

  1999cited by this paper
• Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus.

  1999cited by this paper
• Inhibition of dextran sulphate sodium (DSS)‐induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule‐1 (ELAM‐1) or intercellular adhesion molecule‐1 (ICAM‐1))

  1999cited by this paper
• Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines.

  1999cited by this paper
• p38 MAPK signalling cascades in inflammatory disease.

  1999cited by this paper
• Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I‐labeled anti‐endoglin monoclonal antibodies

  1999cited by this paper
• Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells.

  1999cited by this paper
• Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.

  1999cited by this paper
• ICAM‐3 and E‐selectin endothelial cell expression differentiate two phases of angiogenesis in infantile hemangiomas

  1999cited by this paper
• Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds

  1999cited by this paper
• Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-lpr/lpr mice

  1999cited by this paper
• Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells.

  1999cited by this paper
• Anti-cancer activity of targeted pro-apoptotic peptides

  1999cited by this paper
• Protein tyrosine kinase inhibitors as novel therapeutic agents.

  1999cited by this paper
• Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis.

  1999cited by this paper
• Peptides Mimicking Sialyl‐Lewis A Isolated from a Random Peptide Library and Peptide Array

  1999cited by this paper
• Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist

  1999cited by this paper
• Human Endothelial Cell Life Extension by Telomerase Expression*

  1999cited by this paper
• The cytokine network and immune functions

  1999cited by this paper
• Integrin signaling.

  1999cited by this paper
• Animal models of rheumatoid arthritis.

  1999cited by this paper
• Pyrrolidine Dithiocarbamate Prevents I-κB Degradation and Reduces Microvascular Injury Induced by Lipopolysaccharide in Multiple Organs

  1999cited by this paper
• Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization

  1999cited by this paper
• Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

  1998cited by this paper
• Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature.

  1998cited by this paper
• A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons.

  1998cited by this paper
• Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins.

  1998cited by this paper
• Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis.

  1998cited by this paper
• NF-κB Mediates αvβ3 Integrin-induced Endothelial Cell Survival

  1998cited by this paper
• Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging

  1998cited by this paper
• Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity.

  1998cited by this paper
• Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging.

  1998cited by this paper

• Nanomaterials in Gene Therapy Technology

  2019cites this paper
• Improved efficacy of αvβ3-targeted albumin conjugates by conjugation of a novel auristatin derivative

  2018cites this paper
• New ways in RGD-peptide mediated drug targeting to angiogenic endothelium

  2017cites this paper
• Endothelial-specific delivery of siRNA by novel SAINT-based lipoplexes

  2014cites this paper
• Specific delivery of kinase inhibitors in nonmalignant and malignant diseases

  2012cites this paper
• Targeted siRNA delivery to diseased microvascular endothelial cells—Cellular and molecular concepts

  2011influential citation
• Proteolytically-cleaved Fragments of Cell Surface Proteins Stimulate a Cytotoxic Immune Response Against Tumoractivated Endothelial Cells In vitro

  2010cites this paper
• This information is current as Inflammation Adaptive Immunity , Coagulation , and Endothelial Cells : Directing Innate and Immune Regulation by Microvascular

  2007cites this paper
• New ways in RGD-peptide mediated drug targeting to angiogenic endothelium : On the nature of drugs, linkers, and carriers.

  2007cites this paper
• Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model.

  2007cites this paper
• New ways in RGD-peptide mediated drug targeting to angiogenic endothelium: On the nature of Drugs, Linkers, and Carriers

  2007cites this paper
• Improved efficacy alpha(v)beta(3)-targeted albumin conjugates by conjugation of a novel auristatin derivative

  2007cites this paper
• Rational Design of RGD–Albumin Conjugates for Targeted Delivery of the VEGF‐R Kinase Inhibitor PTK787 to Angiogenic Endothelium

  2006cites this paper
• DNA nanoparticles for gene delivery to cells and tissue

  2006cites this paper
• Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology.

  2006cites this paper
• Design of vascular endothelium-specific drug-targeting strategies for the treatment of cancer.

  2005cites this paper
• Strategies for targeting protein therapeutics to selected tissues and cells

  2004cites this paper
• TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model.

  2004cites this paper
• A novel method for isolation of endothelial cells and macrophages from murine tumors based on Ac-LDL uptake and CD16 expression.

  2004cites this paper
• Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity

  2004cites this paper
• Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study

  2002cites this paper
• Tumor Vasculature Directed Drug Targeting: Applying New Technologies and Knowledge to the Development of Clinically Relevant Therapies

  2002cites this paper